

Certificate of Analysis

Cell count	1.8 million per vial
Viability	92%
CD8+	95%
CD8+M1 Tetramer+	45.8%
CD8+Her2/neu Tetramer+	0.1%
Sterility	Negative for Bacteria, Yeast, Fungi and Mycoplasma

Donor Information


Donor ID	401
Age	29
Gender	Female
Race	Caucasian
Height	5'3"
Weight	277
ABO Type	A positive

HLA typing

	Allele 1	Allele 2
HLA-A	*0201	*0201
HLA-B	*18	*40
HLA-C	*03	*07
HLA-DRB1	*08	*12

Donors are tested for the blood borne pathogens HIV-1 and 2, Hepatitis B, Hepatitis C and HTLV-1 and are negative. Cells should still be handled as if potentially infectious following biosafety level 2 procedures


FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.



Her2/neu Tetramer = Her2/neu₃₆₉₋₃₇₇ peptide: KIFGSLAFL/HLA-A*0201-PE iTag MHC Tetramer (MBL International, Woburn, MA);
M1 tetramer = M1/Flu₅₈₋₆₆ peptide ((GILGFVFTL)/HLA-A*0201-PE iTag MHC Tetramer (MBL International, Woburn, MA)

IFN-gamma Secretion

4664MA20 Anti-M1/Flu T Cells



20,000 T cells were plated in a 96-well round-bottom plate alone or in the presence of 20,000 T2 cells, a B-LCL expressing HLA-A*0201) alone or in the presence of increasing concentrations HLA-A*0201 restricted M1/Flu₅₈₋₆₆ peptide (GILGFVFTL) or HLA-A*0201 restricted CMV pp65 peptide (NLVPMVATV). After an overnight (18-24h) incubation period, supernatant was collected from each well. IFN-γ concentration was analyzed using the Meso Scale Discovery IFN-γ assay.

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.